Preparation For Administration (Store BEOVU in the refrigerator between 2 to 8°C (36 to 46°F); do not freeze. Keep the vial in the outer carton to protect from light.)
Beovu Injection, Solution
Product Images NDC 0078-0827
16 FDA label images from Novartis Pharmaceuticals Corporation · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Beovu (NDC 0078-0827). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Preparation For Administration (Prior to use, the unopened glass vial of BEOVU may be kept at room temperature, 20 to 25°C (68 to 77°F) for up to 24 hours. After opening the glass vial, proceed under aseptic conditions.)
Preparation For Administration (BEOVU is a clear to slightly opalescent and colorless to slightly brownish-yellow solution.)
An instructional diagram showing a syringe with a close-up of the vial interior indicating the 0.05 mL dose volume. It depicts how to draw the precise volume of injection solution before administration.*
Preparation For Administration (BEOVU should be inspected visually upon removal from the refrigerator and prior to administration. If particulates, cloudiness, or discoloration are visible, the glass vial must not be used. The BEOVU kit includes the sterile glass vial and filter needle which are for single use only. Do not use if the packaging, vial and/or filter needle are damaged or expired [see How Supplied/Storage and Handling (16)].)
![Preparation For Administration (BEOVU should be inspected visually upon removal from the refrigerator and prior to administration. If particulates, cloudiness, or discoloration are visible, the glass vial must not be used. The BEOVU kit includes the sterile glass vial and filter needle which are for single use only. Do not use if the packaging, vial and/or filter needle are damaged or expired [see How Supplied/Storage and Handling (16)].)](https://ndclist.com/assets/spl/images/5d1dc1fa-a2d3-46ed-9e9a-c1a036590d3d/rth258-04.jpg)
Figure 1: (Rth258 05)
An illustration showing gloved hands removing the protective cap from a small vial, likely representing preparation for injection. The image suggests aseptic handling of a medication vial but does not specify the product name or details.*
Figure 2: (Rth258 06)
An instructional diagram showing a syringe inserted into a vial containing a solution. A magnified inset highlights the needle inside the vial and the level of liquid within, illustrating proper technique for withdrawing medication.*
Figure 3: (Rth258 07)
Illustration showing a gloved hand holding a syringe filled with liquid while the index finger of the other hand flicks the syringe barrel, a technique often used to remove air bubbles before injection. The syringe includes a needle at the top and measurement markings on the barrel.*
Figure 4: (Rth258 08)
An illustration showing a syringe filled with a liquid solution. A zoomed-in circle highlights the measurement of 0.05 mL, indicating the volume of solution to be delivered via intravitreal injection for the drug Beovu (brolucizumab).*
Figure 5: Mean Change In Visual Acuity From Baseline To Week 96 In Hawk (Rth258 09)
Line graph titled 'HAWK' comparing BCVA changes from baseline (in letters) over 96 weeks between BEOVU (brolucizumab) 6 mg/.05 mL injection and aflibercept 2 mg injection. The x-axis represents time in weeks, and the y-axis shows the BCVA change. Data from 360 subjects per group show initial rapid improvement with stabilization over time, with BEOVU represented by diamond markers and aflibercept by square markers.*
Figure 6: Mean Change In Visual Acuity From Baseline To Week 96 In Harrier (Rth258 10)
A line graph titled 'HARRIER' showing BCVA changes from baseline (letters) on the vertical axis and time in weeks on the horizontal axis. It compares two treatments: BEOVU (n=370) represented by a black line with diamond markers, and Aflibercept 2mg (n=369) represented by a grey line with square markers, over 96 weeks. The graph illustrates trends and differences in BCVA changes for both treatments over time.*
Principal Display Panel Ndc 0078 0827 61 Beovu (brolucizumab-dbll) Injection 6 mg/0.05 mL Single-dose Vial; Discard Unused Portion. For Intravitreal Use Carton Contains: 1 X 2 mL Vial, 1 X Filter Needle Novartis (Rth258 11)
BEOVU 6 mg/0.05 mL injection carton label for intravitreal use containing brolucizumab-dbII. The label states it includes one 2 mL vial and one filter needle. Manufactured by Novartis Pharmaceuticals Corporation, the labeling includes storage instructions and a barcode, with emphasis on discarding unused portions and keeping unopened vials refrigerated.*
Rth258 12
Illustration showing a labeled syringe for BEOVU (brolucizumab) injection, solution. The syringe includes parts labeled as Syringe cap, Luer Lock, 0.05 mL dose mark, Rubber stopper, Finger grip, and Plunger rod.*
Rth258 13
An instructional line drawing showing a hand twisting off the cap from a syringe, indicating the removal of the syringe cap before injection.*
Rth258 14
An instructional illustration showing a hand holding a syringe filled with injection solution. A magnified circular inset highlights the plunger stop inside the syringe barrel, indicating the proper plunger position for the dose. The diagram relates to the preparation or administration of an intravitreal injection.*
Rth258 15
A line graph titled 'KESTREL' comparing visual acuity (VA) change from baseline in letters over time (weeks) for Beovu 6 mg and Aflibercept 2 mg. The x-axis shows time in weeks from 0 to 52, and the y-axis shows VA change from baseline in letters from 0 to 12. Beovu is represented by a black line with diamond markers, and Aflibercept by a gray line with square markers, showing both treatments' VA improvements over 52 weeks with Aflibercept slightly higher at most points.*
Rth258 16
A line graph titled 'KITE' comparing visual acuity (VA) change from baseline in letters over time in weeks (0 to 52 weeks) for BEOVU 6 mg (N=179) and Aflibercept 2 mg (N=181). The vertical axis shows VA change from 0 to 12 letters. BEOVU is represented by a black line, showing a steady increase over time, reaching around 10.5 letters at week 52, while Aflibercept is shown as a gray line with a slightly lower VA change, leveling off near 9.5 letters by week 52.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
